Facebook
Twitter
LinkedIn
ForwardModule 4: Study Conduct
Study Conduct emphasizes components of study conduct and post-trial commitments to address barriers in participation and trust.
Original Release Date: July 15, 2022
Expiration Date: August 15, 2025
Review Date: May 22, 2024 by Willyanne Decormier Plosky, DrPH
Target Audience
This activity is intended for leadership, investigators, practicing providers, clinical trialists, clinical trial staff, nurse practictioners, nurses, research nurse specialists, physician assistants, clinical research coordinators, other frontline staff, regulatory and IRB committee members, and others who design, conduct, report or are responsible for clinical research.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Identify strategies for retention and appropriateness of payment for participation in clinical trials
- Address inclusion of people with disabilities in clinical trials
- Discuss end-of-trial and post-trial responsibilities to participants
Additional Information
PLEASE NOTE: For questions or assistance with any special needs regarding the training course, please contact the MRCT Center at: MRCT@bwh.harvard.edu
YOU MAY ALSO BE INTERESTED IN Interpretation and Application of ICH E6(R2)
Welcome to Version 1.0 of Interpretation and Application of ICH E6(R2) – an online course developed by the MRCT Center with a multi-stakeholder international team of experts.
MANY THANKS TO THE FOLLOWING PEOPLE FOR ACTING AS DISCUSSANTS DURING THIS TRAINING SERIES:
Dr. Christopher S. Lathan, Chief Clinical Access and Equity Officer, Dana-Farber Cancer Institute; Christopher and Constance Hadley Family Chair, Dana-Farber Cancer Institute; Associate Medical Director, Dana-Farber Cancer Institute Network; Associate Professor of Medicine, Harvard Medical School
Dr. Sapna S. McManus; Head of Patient Inclusion & Health Equity and Chief Diversity Officer, Genentech
This activity is not for credit.